Possible correction of defective polymorphonuclear cell functions in type-2 diabetes mellitus by met-enkephalin

Area of Science:

• Immunology
• Endocrinology
• Biochemistry

Background:

• Type-2 diabetes mellitus is associated with neutrophil dysfunction.
• Neutrophil dysfunction in diabetes involves the reactive oxygen species (ROS) generating system.
• Arachidonic acid metabolism and its products, like leukotriene B4 (LTB4), play roles in inflammation.

Purpose of the Study:

• To investigate the effect of Met-enkephalin (Met-Enk) on neutrophil function in type-2 diabetes.
• To explore the potential of Met-Enk as a therapeutic agent for diabetic complications.

Main Methods:

• Human peripheral blood neutrophils (PMNLs) were obtained from patients with type-2 diabetes mellitus.
• In vitro pretreatment of PMNLs with Met-Enk was performed.
• The ROS generating system and LTB4 release were analyzed.

Main Results:

• Met-Enk pretreatment normalized the ROS generating system in neutrophils from type-2 diabetes patients.
• A consecutive increase in LTB4 release was observed following Met-Enk treatment.
• These findings suggest a modulating effect of Met-Enk on arachidonic acid metabolism.

Conclusions:

• Met-enkephalin demonstrates a normalizing effect on neutrophil ROS generation in type-2 diabetes.
• Met-Enk may influence neutrophil function through modulation of arachidonic acid metabolism and LTB4 production.
• Further research is warranted to explore Met-Enk's therapeutic potential in diabetic inflammatory conditions.